MYOS RENS Technology, Inc. :MYOS-US: Earnings Analysis: Q4, 2016 By the Numbers : April 6, 2017

MYOS RENS Technology, Inc. reports financial results for the quarter ended December 31, 2016.

Highlights

  • Summary numbers: Revenues of USD 0.03 million, Net Earnings of USD -0.75 million.
  • Gross margins widened from -1,042.86% to -196.30% compared to the same period last year, operating (EBITDA) margins now 48.15% from -3,508.57%.
  • Change in operating cash flow of -128.47% compared to same period last year is about the same as change in earnings, likely no significant movement in accruals or reserves.
  • Earnings growth from operating margin improvements as well as one-time items.

The table below shows the preliminary results and recent trends for key metrics such as revenues and net income growth:

2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31
Relevant Numbers (Quarterly)
Revenues (mil) 0.03 0.04 0.07 0.2 0.04
Revenue Growth (%YOY) -22.86 8.33 -19.51 3150 218.18
Earnings (mil) -0.75 -0.87 -1.5 -1.22 -1.3
Earnings Growth (%YOY) 42.06 33.08 -57.05 20.21 -50.93
Net Margin (%) -2785.19 -2220.51 -2277.27 -625.64 -3708.57
EPS -0.14 -0.17 -0.3 -0.31 -0.39
Return on Equity (%) -56.55 -60.4 -87.95 -88.5 -128.09
Return on Assets (%) -47.78 -48.69 -72.57 -68.19 -93.04

Access our Ratings and Scores for MYOS RENS Technology, Inc.

Market Share Versus Profits

Revenues History
Earnings History

Compared to the same period last year, MYOS-US‘s change in revenue was close to the amount of its change in earnings. It remains to be seen how the rest of its peer group’s results will turn out and if MYOS-US‘s performance is a sign of any major shift in the composition of market share in this sector. Also, for comparison purposes, revenues changed by -30.77% and earnings by 13.16% compared to the previous period.

Earnings Growth Analysis

The company’s earnings growth was influenced by year-on-year improvement in gross margins from -1,042.86% to -196.30% as well as better cost controls. As a result, operating margins (EBITDA margins) rose from -3,508.57% to 48.15% compared to the same period last year. For comparison, gross margins were -112.82% and EBITDA margins were -2,023.08% in the last reporting period.

Gross Margin Trend

Companies sometimes sacrifice improvements in revenues and margins in order to extend friendlier terms to customers and vendors. Capital Cube probes for such activity by comparing the changes in gross margins with any changes in working capital. If the gross margins improved without a worsening of working capital, it is possible that the company’s performance is a result of truly delivering in the marketplace and not simply an accounting prop-up using the balance sheet.

Gross Margin History
Working Capital Days History

MYOS-US‘s gross margin improvement has not produced any big difference in its working capital. Working capital days are currently 11,457.57, compared to last year’s level of 4,897.10 days. This leads Capital Cube to conclude that the improvements in gross margins are likely from operating decisions and not trade-offs with the balance sheet.

Cash Versus Earnings – Sustainable Performance?

It is important to examine a company�s cash versus earnings numbers to gauge whether its performance is sustainable.

MYOS-US‘s year-on-year change in operating cash flow of -128.47% is around its change in earnings. This suggests that there are likely no significant movement in accruals or reserves for managing earnings this period.

Margins

The company’s earnings growth has also been influenced by the following factors: (1) Improvements in operating (EBIT) margins from -3,697.14% to -196.30% and (2) one-time items. The company’s pretax margins are now -2,785.19% compared to -3,708.57% for the same period last year.

EBIT Margin History
PreTax Margin History

Access our Ratings and Scores for MYOS RENS Technology, Inc.

Company Profile

MYOS RENS Technology, Inc. engages in the discovery, development, and commercialization of therapeutic products, nutritional supplements, and other technologies aimed at improving the health and performance of muscle tissue. The firm offers bionutrition products and biotherapeutic research. Bionutrition products involves Re Muscle Health, which seeks to rebuild, rejuvenate, and maintain lean muscles. The company was founded on April 11, 2007 and is headquartered in Cedar Knolls, NJ.

CapitalCube does not own any shares in the stocks mentioned and focuses solely on providing unique fundamental research and analysis on approximately 50,000 stocks and ETFs globally. Try any of our analysis, screener or portfolio premium services free for 7 days. To get a quick preview of our services, check out our free quick summary analysis of MYOS-US.